Kaleo said today that despite ongoing manufacturing delays reported by epinephrine auto-injector manufacturers, Kaleo’s Auvi-Q device is available via prescription and that the privately-held company has ‘sufficient supply to meet any anticipated demand.’ Kaleo’s epinephrine auto-injector features voice instructions that guide users through the drug-delivery process and an auto-retractable needle system, according to the company. […]
Impax Laboratories
Impax settles ‘fax-blasting’ class action suit over EpiPen alternative
Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week. The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company […]
Express Scripts covers Mylan’s EpiPen on 2018 formulary, excluding rivals
Express Scripts (NSDQ:ESRX) said yesterday that it would include Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax Laboratories (NSDQ:IPXL) and Kaleo. The largest pharmacy benefit manager in the U.S. has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards […]
Adamis up, Mylan down on generic EpiPen approval
Shares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%. For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors. Adamis’ device, called Symjepi, is intended to be a cheaper […]
Impax shares climb despite Q1 miss
Shares in Impax Laboratories (NSDQ:IPXL) rose earlier this week even though the pharmaceutical company missed expectations on Wall Street with its Q1 results. The Hayward, Calif.-based company posted profits of $7.7 million on sales of $184.4 million for the 3 months ended March 31, for bottom-line loss of -75% on sales loss of -18.2% compared with the same […]
Demand for EpiPen alternatives jumps as states consider access legislation
Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007. Generic […]
CVS to sell cheaper, generic version of Impax’s allergy injection
CVS Health Corp. (NYSE:CVS) said today that it will start selling a generic version of Impax Laboratories‘ (NSDQ:IPXL) emergency allergy injection, Adrenaclick. The device is similar to Mylan‘s (NSDQ:MYL) EpiPen, although regulators do not consider the 2 devices to be exactly the same. The Adrenaclick has a list price of more than $400, but the generic […]
